`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MASSACHUSETTS
`
`
`
`
`TEVA PHARMACEUTICALS
`INTERNATIONAL GMBH and
`TEVA PHARMACEUTICALS
`USA, INC.,
`
`Plaintiffs,
`
`
`v.
`
`ELI LILLY AND COMPANY,
`Defendant.
`
`Civil Action No.
`1:18-cv-12029-ADB
`
`
`
`
`
`
`
`
`
`PLAINTIFFS TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`AND TEVA PHARMACEUTICALS USA, INC.’S MOTION FOR PARTIAL
`SUMMARY JUDGMENT REGARDING JUDICIAL ESTOPPEL
`
`Pursuant to Federal Rule of Civil Procedure 56 and Local Rule 56.1, Plaintiffs Teva
`
`Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. (together, “Teva”)
`
`move for partial summary judgment that Lilly is judicially estopped from taking positions in this
`
`case that directly conflict with position Lilly took in inter parties review proceedings and that were
`
`accepted by the Patent Trial and Appeal Board. See Eli Lilly & Co. v. Teva Pharms. Int’l GmbH,
`
`2020 WL 806932 (PTAB Feb. 18, 2020); Eli Lilly & Co. v. Teva Pharms. Int’l GmbH, 2020 WL
`
`808240 (PTAB Feb. 18, 2020). Pursuant to Fed. R. Civ. P. 56(g), Teva also moves to have the
`
`following facts be deemed established for purposes of this case:
`
`1. Anti-CGRP antagonist antibodies were well-known in the art as of 2005.
`
`2. By 2005, a POSA would have considered the techniques for generating anti-CGRP
`
`antagonist antibodies to be “routine” and “conventional.”
`
`3. By 2005, the techniques for preparing humanized antibodies from non-human
`
`antibodies were well-established and conventional to a POSA.
`
`
`
`1
`
`
`
`Case 1:18-cv-12029-ADB Document 423 Filed 07/27/22 Page 2 of 5
`
`4. By 2005, conventional humanization techniques that were routinely used preserved the
`
`affinity and specificity of the donor antibody.
`
`5. By 2005, assays that measured antagonism, such as cAMP activation assays and
`
`radioligand binding assays, were conventional and routine means of evaluating whether
`
`an anti-CGRP antibody was in fact able to antagonize CGRP.
`
`In addition to the Memorandum, this Motion is supported by Teva’s Statement of
`
`Uncontested Material Facts and the Declaration of Elaine Herrmann Blais.
`
`REQUEST FOR ORAL ARGUMENT
`
`Pursuant to Local Rule 7.1(d), Teva respectfully requests oral argument.
`
`
`
`
`
`
`2
`
`
`
`Case 1:18-cv-12029-ADB Document 423 Filed 07/27/22 Page 3 of 5
`
`Respectfully Submitted,
`
`/s/ Elaine Herrmann Blais
`Douglas J. Kline (BBO# 556680)
`Elaine Herrmann Blais (BBO# 656142)
`Robert Frederickson III (BBO# 670111)
`Joshua S. Weinger (BBO# 690814)
`Alexandra Lu (BBO# 691114)
`Eric T. Romeo (BBO# 691591)
`Kathleen A. McGuinness (BBO# 693760)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`dkline@goodwinlaw.com
`eblais@goodwinlaw.com
`rfrederickson@goodwinlaw.com
`jweinger@goodwinlaw.com
`alu@goodwinlaw.com
`eromeo@goodwinlaw.com
`kmcguinness@goodwinlaw.com
`
`I. Neel Chatterjee (pro hac vice)
`GOODWIN PROCTER LLP
`601 Marshall St.
`Redwood City, CA 94063
`Tel.: (650) 752-3100
`Fax: (650) 853-1038
`nchatterjee@goodwinlaw.com
`
`Natasha E. Daughtrey (pro hac vice)
`GOODWIN PROCTER LLP
`601 S. Figueroa St.
`Los Angeles, CA 90017
`Tel.: (213) 426-2500
`Fax: (213) 623-1673
`ndaughtrey@goodwinlaw.com
`
`Attorneys for Plaintiffs
`
`
`
`
`Dated: March 28, 2022
`
`
`
`
`
`
`
`3
`
`
`
`Case 1:18-cv-12029-ADB Document 423 Filed 07/27/22 Page 4 of 5
`
`LR 7.1(a)(2) CERTIFICATION
`
`I, Elaine Herrmann Blais, hereby certify that Plaintiffs’ counsel conferred with Defendant’s
`
`counsel regarding this motion and attempted in good faith to resolve or narrow the issues presented
`
`in this motion. Lilly opposes this motion.
`
`/s/ Elaine Herrmann Blais
`Elaine Herrmann Blais
`
`4
`
`
`
`Case 1:18-cv-12029-ADB Document 423 Filed 07/27/22 Page 5 of 5
`
`CERTIFICATE OF SERVICE
`
`I, Elaine Hermann Blais, hereby certify that this document filed through the ECF system
`
`will be sent electronically to the registered participants as identified on the Notice of Electronic
`
`Filing (“NEF”) and paper copies will be sent to those indicated as non-registered participants
`
`on July 27, 2022.
`
`/s/ Elaine Herrmann Blais
`Elaine Herrmann Blais (BBO# 656142)
`GOODWIN PROCTER LLP
`100 Northern Avenue
`Boston, MA 02210
`Tel.: (617) 570-1000
`Fax: (617) 523-1231
`eblais@goodwinlaw.com
`
`